Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 4 records in total 4
    records per page

    Results of Favipiravir Combined Treatment in Intensive Care Patients With Covid-19 MESHD

    Authors: Habip Yilmaz; Emre Güner; Murat Altuntas

    doi:10.21203/ Date: 2020-12-19 Source: ResearchSquare

    Aim: Covid-19 MESHD ( Coronavirus disease 2019 MESHD) is a disease that has already taken place in human history. Although there is still no effective treatment and vaccine protocol, different treatment options are being tried. In this study, it was aimed to determine the basic characteristics and changes in laboratory findings of patients who were hospitalized with the diagnosis of Covid-19 MESHD in the intensive care unit and underwent treatment protocol containing favipiravir.Material and Method: It was carried out with the data of 179 inpatients in an intensive care unit between 01.06.2020 - 30.06.2020. The inclusion criterias of the study are to have a diagnosis of COVID-19 MESHD confirmed by PCR test, to be hospitalized in the intensive care unit, receiving therapy combined with favipravir and to have access to its data through the automation system. According to literature; the sociodemographic characteristics, some basic characteristics and some laboratory findings of the patients were evaluated. Statistical analyzes were performed using the Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corp .; Armonk, NY, USA).Findings: The average age of the study group is 60.9±16.4 years and 65.9% (n:118) of them are male. According to the clinical classification, more than half (50.8%, n: 91) are included in the "high" clinical classification. The most common chronic disease MESHD is " hypertension MESHD ( HT MESHD)" (42.5%, n:76) and the most common symptom is " fever MESHD" (57.5%, n: 103). While 82.7% (n: 148) have widespread CT (Computed tomography) findings, CPR HGNC ( C-Reactive protein HGNC) positivity rate is 65.4% (n: 117). Statistical significant difference was detected between three measurements of blood urea nitrogen (BUN), aspartat aminotransferase ( AST HGNC), alanin aminotransfrase (ALT), CRP HGNC between the 1st and the 3rd day. Conclusion: Favipiravir demonstrates a proper safety profile. However, its side effects teratogenicity, hyperuricaemia and QTc MESHD (corrected QT interval) prolongation have not yet been adequately studied. It may be safe and tolerable in short-term use, but more evidence is needed to assess the longer-term effects of treatment.

    Risk Factors Analysis of COVID-19 MESHD Patients with ARDS MESHD and Prediction Based on Machine Learning

    Authors: Wan Xu; Nan-Nan Sun; Hai-Nv Gao; Zhi-Yuan Chen; Ya Yang; Bin Ju; Ling-Ling Tang

    doi:10.21203/ Date: 2020-09-15 Source: ResearchSquare

    COVID-19 MESHD is a newly emerging infectious disease MESHD, which is generally susceptible to human beings and has caused huge losses to people's health. Acute respiratory distress syndrome MESHD ( ARDS MESHD) is one of the common clinical manifestations of severe COVID-19 MESHD and it is also responsible for the current shortage of ventilators worldwide. This study aims to analyze the clinical characteristics of COVID-19 MESHD ARDS MESHD patients and establish a diagnostic system based on artificial intelligence (AI) method to predict the probability of ARDS in COVID-19 MESHD patients. We collected clinical data of 659 COVID-19 MESHD patients from 11 regions in China. The clinical characteristics of the ARDS group and no-ARDS group of COVID-19 MESHD patients were elaborately compared and both traditional machine learning algorithms MESHD and deep learning-based method were used to build the prediction models. Results indicated that the median age of ARDS MESHD patients was 56.5 years old, which was significantly older than those with non-ARDS by 7.5 years. Male and patients with BMI>25 were more likely to develop ARDS MESHD. The clinical features of ARDS MESHD patients included cough (80.3%), polypnea (59.2%), lung consolidation (53.9%), secondary bacterial infection MESHD (30.3%), and comorbidities such as hypertension MESHD (48.7%). Abnormal biochemical indicators such as lymphocyte count, CK, NLR, AST HGNC, LDH, and CRP HGNC were all strongly related to the aggravation of ARDS. Furthermore, through various AI methods for modeling and prediction effect evaluation based on the above risk factors, decision tree achieved the best AUC, accuracy, sensitivity and specificity in identifying the mild patients who were easy to develop ARDS MESHD, which undoubtedly helped to deliver proper care and optimize use of limited resources.

    The characteristics and death risk factors of 132 COVID-19 MESHD pneumonia patients with comorbidities: a retrospective single center analysis in Wuhan, China

    Authors: Chen Chen; Zhang Jing Yi; Li Chang; Hu Zhi Shuo; Zhang Ming; Tu Pei; Liu Lei; Zong Wen Xia

    doi:10.1101/2020.05.07.20092882 Date: 2020-05-12 Source: medRxiv

    Background: The new coronavirus pneumonia MESHD ( COVID-19 MESHD) has evolved into a global pandemic disease, and the epidemiological characteristics of the disease have been reported in detail. However, many patients with new coronary pneumonia MESHD have comorbidities, and there are few researches reported in this special population. Methods: a retrospective analysis was performed on 132 consecutive COVID-19 MESHD patients with comorbidities from January 19, 2020 to March 7, 2020 in Hubei NO.3 People Hospital. Patients were divided into mild group and critical group and were followed up to the clinical endpoint. The observation biomarkers include the clinical feature, blood routine, blood biochemistry, inflammation MESHD biomarkers, and coagulation function. Univariate and multivariate logistic regression was used to analyze the risk factors associated with death MESHD. Results: 132 patients were enrolled in this study and divided into the mild group (n=109, 82.6%) and critical group (n=23, 17.4%), of whom 119 were discharged and 13 were died in hospital. The all-cause mortality rate was 9.8%, of which 7 patients died of respiratory failure MESHD, 5 patients died of heart failure MESHD, and 1 patient died of chronic renal failure MESHD. There was significant statistical difference of mortality rates between the mild group (5.5%) and the critical group (30.4%).The average time of hospitalization was 16.9 (9, 22) days. Hypertension MESHD was the most common comorbidity (n=90, 68.2%), followed by diabetes MESHD (n=45, 34.1%), coronary heart disease MESHD (31, 23.5%). Compared with the mild group, the patients were older in critical group (P <0.05), and neutrophils, neutrophil ratio, neutrophil-lymphocyte ratio (NLR), serum urea nitrogen (BUN), procalcitonin (PCT), C-reactive protein CRP), serum amyloid protein ( SSA HGNC), N-terminal brain natriuretic peptide precursor (NT-pro BNP) were significantly increased (P <0.05). However, lymphocytes lymphocyte ratio, albumin were lower than those in the critical group (P <0.05). The patients were further divided into the survivor group (n=119, 90.2%) and the non-survivor group (n=13, 9.8%). Compared with the survivor group, the death rate of patients with coronary heart disease MESHD was significantly increased (53.8% vs 20.2%), and The neutrophil ratio, aspartate aminotransferase ( AST HGNC), BUN, PCT, CRP HGNC, SAA, interleukin-6 HGNC( IL-6 HGNC) and D-dimer were significantly increased (P <0.05), while the lymphocytes and NLR reduced (P <0.05). Multivariate logistic stepwise regression analysis showed that the past medical history of coronary heart disease MESHD[OR:2.806 95%CI:0.971~16.795], decreased lymphocytes[OR:0.040, 95%CI:0.001~2.306], increased AST HGNC[OR:1.026, 95%CI:1.000~1.052], increased SSA HGNC[OR:1.021, 95%CI:1.001~1.025], and increased D-dimer[OR:1.231, 95%CI:1.042~1.456] are risk factors associated with death MESHD in COVID-19 MESHD patients pneumonia MESHD with comorbidities. Conclusion: The mortality rate of COVID-19 MESHD patients with coronary heart disease MESHD is relatively high. In all patients, the lower lymphocytes, and higher NLR, BUN, PCT, CRP HGNC, SSA HGNC, D-dimer are significant characteristics. The past medical history of coronary heart disease MESHD, decreased lymphocytes, increased AST HGNC, SSA HGNC and D-dimer are risk factors associated with death MESHD in COVID-19 MESHD pneumonia MESHD patients with comorbidities

    Risk factors and clinical features of deterioration in COVID-19 MESHD patients in Zhejiang, China: a single- centre, retrospective study

    Authors: Ping Yi; Xiang Yang; Cheng Ding; Yanfei Chen; Kaijin Xu; Qing Ni; Hong Zhao; Yongtao Li; Xuan Zhang; Jun Liu; Jifang Sheng; Lanjuan Li

    doi:10.21203/ Date: 2020-04-11 Source: ResearchSquare

    BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD swept through Wuhan and spread across China and overseas beginning in December 2019. To identify predictors associated with disease progression, we evaluated clinical risk factors for exacerbation of SARS-CoV-2 infection MESHD.MethodsA retrospective analysis was used for PCR-confirmed COVID-19 MESHD ( coronavirus disease 2019 MESHD)-diagnosed hospitalized cases between January 19, 2020, and February 19, 2020, in Zhejiang, China. We systematically analysed the clinical characteristics of the patients and predictors of clinical deterioration.ResultsOne hundred patients with COVID-19 MESHD, with a median age of 54 years, were included. Among them, 49 patients (49%) had severe and critical disease MESHD. Age ([36-58] vs [51-70], P=0.0001); sex (49% vs 77.6%, P=0.0031); Body Mass Index (BMI ) ([21.53-25.51] vs [23.28-27.01], P=0.0339); hypertension MESHD (17.6% vs 57.1%, P<0.0001); IL-6 HGNC ([6.42-30.46] vs [16.2-81.71], P=0.0001); IL-10 HGNC ([2.16-5.82] vs [4.35-9.63], P<0.0001); T lymphocyte count ([305- 1178] vs [167.5-440], P=0.0001); B lymphocyte count ([91-213] vs [54.5-163.5], P=0.0001); white blood cell count ([3.9-7.6] vs [5.5-13.6], P=0.0002); D2 dimer ([172-836] vs [408-953], P=0.005), PCT ([0.03-0.07] vs [0.04-0.15], P=0.0039); CRP HGNC ([3.8-27.9] vs [17.3-58.9], P<0.0001); AST HGNC ([16, 29] vs [18, 42], P=0.0484); artificial liver therapy (2% vs 16.3%, P=0.0148); and glucocorticoid therapy (64.7% vs 98%, P<0.0001) were associated with the severity of the disease. Age and weight were independent risk factors for disease severity.ConclusionDeterioration among COVID-19 MESHD-infected patients occurred rapidly after hospital admission. In our cohort, we found that multiple factors were associated with the severity of COVID19 MESHD. Early detection and monitoring of these indicators may reduce the progression of the disease. Removing these factors may halt the progression of the disease. In addition, Oxygen support, early treatment with low doses of glucocorticoids and liver therapy, when necessary, may help reduce mortality in critically ill MESHD patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.